CO5700733A2 - Acidos aminocarboxilicos sustituidos - Google Patents

Acidos aminocarboxilicos sustituidos

Info

Publication number
CO5700733A2
CO5700733A2 CO05121629A CO05121629A CO5700733A2 CO 5700733 A2 CO5700733 A2 CO 5700733A2 CO 05121629 A CO05121629 A CO 05121629A CO 05121629 A CO05121629 A CO 05121629A CO 5700733 A2 CO5700733 A2 CO 5700733A2
Authority
CO
Colombia
Prior art keywords
carbon atoms
alkyl
aryl
alkanoyl
alkoxy
Prior art date
Application number
CO05121629A
Other languages
English (en)
Inventor
Darren Whitehouse
Shaojing Hu
Zandt Michael C Van
Garrett Parker
Original Assignee
Inst For Pharm Discovery Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst For Pharm Discovery Llc filed Critical Inst For Pharm Discovery Llc
Publication of CO5700733A2 publication Critical patent/CO5700733A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/56—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

1.- Un compuesto de la fórmula I:y las sales farmacéuticamente aceptables de los mismos, caracterizado porque R1 es hidrógeno, alquilo de 1 a 6 átomos de carbono, fenil(alquilo de 1 a 6 átomos de carbono), o alquenilo de 3 a 6 átomos de carbono;R6 y R7 son independientemente hidrógeno, alquilo de 1 a 6 átomos de carbono, aril(alquilo de 1 a 6 átomos de carbono), alcanoilo de 1 a 6 átomos de carbono opcionalmente sustituido con 1 ó 2 grupos independientemente seleccionado de amino, mono o dialquilamino, -NH-arilo, -N(alquil de 1 a 6 átomos de carbono)arilo, y CO2H, aril(alcanoilo de 1 a 6 átomos de carbono), alcoxicarbonilo de 1 a 6 átomos de carbono, arilalcoxicarbonilo, heteroariIcarbonilo, heteroarilo, heterocicloalquilcarbonilo, -C(O)NH2, -C(O)NH(alquilo de 1 a 6 átomos de carbono), -C(O)N(alquil de 1 a 6 átomos de carbono)(alquilo de 1 a 6 átomos de carbono), -C(=NH)NH2, -C(=N-C(O)(alcoxi de 1 a 6 átomos de carbono)NH-C(O)(alcoxi de 1 a 6 átomos de carbono), o -SO2-arilo, en donde las porciones cíclicas de cada uno de los anteriores están opcionalmente sustituidas con 1, 2, 3 ó 4 grupos que son independientemente halógeno, alquilo de 1 a 6 átomos de carbono, alcoxi de 1 a 6 átomos de carbono, NO2, OH, CO2H, CN, alcanoilo de 2 a 6 átomos de carbono, NH2, NH(alquilo de 1 a 6 átomos de carbono), N(alquil de 1 a 6 átomos de carbono)(alquilo de 1 a 6 átomos de carbono), haloalquilo o haloalcoxi;R8 es hidrógeno, alquilo de 1 a 6 átomos de carbono, aril(alquilo de 1 a 6 átomos de carbono), aril(alcanoilo de 1 a 6 átomos de carbono), en donde el grupo arilo está opcionalmente sustituido con alquilo de 1 a 4 átomos de carbono, alcoxi de 1 a 4 átomos de carbono, halógeno, NO2, haloalquilo de 1 a 4 átomos de carbono, o haloalcoxi de 1 a 4 átomos de carbono;R20, R21, R22 y R23 son independientemente seleccionados de hidrógeno, arilalcoxi, arilalquilo, halógeno, alquilo, ...
CO05121629A 2003-04-30 2005-11-30 Acidos aminocarboxilicos sustituidos CO5700733A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46687003P 2003-04-30 2003-04-30

Publications (1)

Publication Number Publication Date
CO5700733A2 true CO5700733A2 (es) 2006-11-30

Family

ID=33434991

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05121629A CO5700733A2 (es) 2003-04-30 2005-11-30 Acidos aminocarboxilicos sustituidos

Country Status (15)

Country Link
US (1) US7358248B2 (es)
EP (1) EP1622886A2 (es)
JP (1) JP2006525364A (es)
KR (1) KR20050115337A (es)
CN (1) CN1812979A (es)
AU (1) AU2004236247B2 (es)
BR (1) BRPI0409924A (es)
CA (1) CA2523718A1 (es)
CO (1) CO5700733A2 (es)
EA (1) EA200501715A1 (es)
MX (1) MXPA05011537A (es)
NO (1) NO20054958L (es)
RS (1) RS20050814A (es)
WO (1) WO2004099171A2 (es)
ZA (1) ZA200509630B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078448A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
EP1622886A2 (en) 2003-04-30 2006-02-08 The Institutes for Pharmaceutical Discovery, LLC Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
MX2007000481A (es) 2004-07-14 2007-03-29 Ptc Therapeutics Inc Metodos para tratar hepatitis c.
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CN101022802A (zh) 2004-07-22 2007-08-22 Ptc医疗公司 用于治疗丙型肝炎的噻吩并吡啶化合物
US20060094747A1 (en) * 2004-10-28 2006-05-04 The Institute For Pharmaceutical Discovery, L.L.C. Substituted carboxylic acids
CA2588776A1 (en) * 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Substituted amino carboxylic acids
JP2008520683A (ja) * 2004-11-18 2008-06-19 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー タンパク質チロシンホスファターゼ阻害剤としてのヘテロシクリルビフェニル誘導体
DE102004060542A1 (de) 2004-12-16 2006-07-06 Sanofi-Aventis Deutschland Gmbh Hydroxybiphenyl-Carbonsäuren und Derivate, Verfahren zu deren Herstellung und deren Verwendung
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2006084033A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
ES2386299T3 (es) 2006-02-03 2012-08-16 Bionomics Limited Benzofuranos, benzotiofenos, benzoselenofenos e indoles sustituidos y su uso como inhibidores de la polimerización de tubulina
WO2008033931A1 (en) * 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib
WO2008033455A2 (en) * 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
EP2226320A4 (en) * 2007-12-26 2012-07-11 Eisai R&D Man Co Ltd PROCESS FOR THE PRODUCTION OF A HETEROCYCLE-SUBSTITUTED PYRIDINE DERIVATIVE
CN101945652A (zh) * 2008-02-14 2011-01-12 西格纳姆生物科学公司 抑制异戊二烯基-s-半胱氨酰基甲基转移酶的乙酰基模拟化合物
AU2009239430B2 (en) 2008-04-21 2015-01-22 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
MA33364B1 (fr) 2009-05-28 2012-06-01 Novartis Ag Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
ES2602826T3 (es) 2009-05-28 2017-02-22 Novartis Ag Derivados aminobutíricos sustituidos como inhibidores de neprilisina
CN102030700B (zh) * 2009-09-30 2016-06-01 中国医学科学院药物研究所 苯甲酰胺基羧酸类化合物及其制法和药物用途
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
JP5814031B2 (ja) * 2010-07-30 2015-11-17 ユー・ディー・シー アイルランド リミテッド 有機電界発光素子、及びジベンゾチオフェン構造又はジベンゾフラン構造を有する有機電界発光素子用材料
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
AP2015008621A0 (en) 2013-02-14 2015-07-31 Novartis Ag Substituted bisphenyl butanoic nep 'neutral endopeptidase' inhibitors
WO2014126972A1 (en) 2013-02-14 2014-08-21 Novartis Ag Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy
US20170022171A1 (en) 2014-04-03 2017-01-26 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentanecarboxylic acids and their use
US20170114049A1 (en) 2014-04-03 2017-04-27 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratory tract diseases
CN106458938A (zh) 2014-04-03 2017-02-22 拜耳制药股份公司 手性2,5‑二取代的环戊烷甲酸衍生物及其用途
WO2020023620A1 (en) * 2018-07-25 2020-01-30 Trustees Of Boston College Methods and compositions of chemically modified phage libraries
US11655468B2 (en) 2018-07-25 2023-05-23 The Trustees Of Boston College Methods and compositions of chemically modified phage libraries

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950542A (en) * 1967-02-21 1976-04-13 L'oreal Cysteamine derivatives for oral treatment of seborrhea
FR2531083B1 (fr) 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
EP0254032A3 (en) * 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4863919A (en) 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
EP0798291B1 (en) * 1994-12-14 2002-09-11 Santen Pharmaceutical Co., Ltd. Novel 1,3-dialkylurea derivatives
GB9518553D0 (en) * 1995-09-11 1995-11-08 Fujisawa Pharmaceutical Co New urea derivatives processes for the preparation thereof and pharmaceutical composition comprising the same
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6232322B1 (en) * 1998-05-12 2001-05-15 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
AU6903200A (en) * 1999-08-16 2001-03-13 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
JP2006525365A (ja) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー フェニル置換カルボン酸
EP1622886A2 (en) 2003-04-30 2006-02-08 The Institutes for Pharmaceutical Discovery, LLC Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
CA2588776A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Substituted amino carboxylic acids

Also Published As

Publication number Publication date
KR20050115337A (ko) 2005-12-07
US20040266789A1 (en) 2004-12-30
NO20054958L (no) 2006-01-23
BRPI0409924A (pt) 2006-04-25
MXPA05011537A (es) 2006-01-23
US7358248B2 (en) 2008-04-15
EA200501715A1 (ru) 2006-06-30
EP1622886A2 (en) 2006-02-08
CN1812979A (zh) 2006-08-02
WO2004099171A3 (en) 2005-03-31
AU2004236247B2 (en) 2008-11-06
CA2523718A1 (en) 2004-11-18
NO20054958D0 (no) 2005-10-25
JP2006525364A (ja) 2006-11-09
RS20050814A (en) 2008-04-04
WO2004099171A2 (en) 2004-11-18
ZA200509630B (en) 2007-02-28
AU2004236247A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
CO5700733A2 (es) Acidos aminocarboxilicos sustituidos
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
CY1105899T1 (el) Πυριδινοϋλοπιπepιδινες ως 5-ht1f αγωνιστες
DE60301345D1 (de) Stabilisierte askorbinsäurederivate
WO2003106628A3 (en) BENZFIAZEPINE F1F0 ATP HYDROLASE MITOCHONDRIAL INHIBITORS AND METHODS OF INHIBITING F1F0 ATP HYDROLASE
TW200606137A (en) Urea derivatives
EA199900591A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха
ES2189234T3 (es) Nuevos derivados de taxano.
BRPI0510598A (pt) compostos de amida de aril ou heteroaril substituìdos
MY126139A (en) Piperidine compounds for use as ccr-3 inhibitors
BRPI0409105A (pt) análogos de quinobenzoxazina substituìdos
ATE337326T1 (de) Hemmer des phosphattransports
CY1113359T1 (el) Αντι-νεοπλασιακα παραγωγα του et-743
ES2177275T3 (es) Derivados de oxadiazolina y su uso como insecticidas.
DK0870763T3 (da) Kondenserede piperidinderivater som inhibitorer for syntese af nitrogenmonoxid
YU43902A (sh) Novi razgranati supstituisani amino derivati od 3-amino-1- -fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
IS7911A (is) Ímídasólafleiður með sækni í alfa 2 viðtakavirkni
EA200101103A1 (ru) НОВЫЕ 15-ЧЛЕННЫЕ 8а- И 9а ЛАКТАМЫ
DE69319900D1 (de) N,n'-disubstituierte amidderivate
AR041556A1 (es) Compuestos de 1- aril - dihidropiridona con actividad antimicrobiana
RS51051B (sr) Heksaciklična jedinjenja
TW330147B (en) Halogenobenzimidazoles, their preparation processes and their use
GB0412893D0 (en) Novel antiviral macrocycle derivatives and metal complexes, incorporating bridged macrocycles
ATE552003T1 (de) Chinoxalinderivate
CO4940470A1 (es) Compuestos 5,6,7-trisustituidos-4-aminopirido[2,3-d]pirimi- dina

Legal Events

Date Code Title Description
FA Application withdrawn